[1] Mignogna MD, Fedele S, Lo Russo L.The World Cancer Report and the burden of oral cancer[J]. Eur J Cancer Prev, 2004,13(2):139-142. [2] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. [3] Langfelder P, Horvath S.WGCNA: an R package for weighted correlation network analysis[J]. BMC Bioinformatics, 2008, 9: 559. [4] Zhu YF, Qi M.Expression and prognostic roles of PABPC1 in hepatocellular carcinoma[J]. Int J Surg, 2020, 84: 3-12. [5] Uhlén M, Björling E, Agaton C, et al.A human protein atlas for normal and cancer tissues based on antibody proteomics[J]. Mol Cell Proteomics, 2005, 4(12): 1920-1932. [6] Li T, Fu J, Zeng Z, et al.TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(W1): W509-W514. [7] Azimi F, Scolyer RA, Rumcheva P,et al.Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma[J]. J Clin Oncol, 2012, 30(21):2678-2683. [8] Mehrotra R,Gupta DK.Exciting new advances in oral cancer diagnosis: avenues to early detection[J]. Head Neck Oncol, 2011, 3: 33. [9] Di Martino JS, Nobre AR, Mondal C, et al.A tumor-derived type Ⅲ collagen-rich ECM niche regulates tumor cell dormancy[J]. Nat Cancer, 2022. 3(1): 90-107. [10] Fang M, Yuan J, Peng C, et al.Collagen as a double-edged sword in tumor progression[J]. Tumour Biol, 2014, 35(4): 2871-2882. [11] Siddhartha R, Garg M.Molecular and clinical insights of matrix metalloproteinases into cancer spread and potential therapeutic interventions[J]. Toxicol Appl Pharmacol, 2021, 426: 115593. [12] Adeshakin FO, Adeshakin AO, Afolabi LO, et al.Mechanisms for modulating anoikis resistance in cancer and the relevance of metabolic reprogramming[J]. Front Oncol, 2021, 11: 626577. [13] Sorokin L.The impact of the extracellular matrix on inflammation[J]. Nat Rev Immunol, 2010, 10(10):712-723. [14] Dhanda J, Triantafyllou A, Liloglou T, et al.SERPINE1 and SMA expression at the invasive front predict extracapsular spread and survival in oral squamous cell carcinoma[J]. Br J Cancer, 2014, 111(11): 2114-2121. [15] Yu J, Lou Y, Hou M, et al.Circ_0058063 contributes to oral squamous cell carcinoma development by sponging miR-145-5p and upregulating SERPINE1[J]. J Oral Pathol Med, 2022, 51(7): 630-637. [16] Li X, Wang C, Zhang H, et al.circFNDC3B accelerates vasculature formation and metastasis in oral squamous cell carcinoma[J]. Cancer Res, 2023,83(9):1459-1475. [17] Tian S, Peng P, Li J, et al.SERPINH1 regulates EMT and gastric cancer metastasis via the Wnt/β-catenin signaling pathway[J]. Aging (Albany NY), 2020, 12(4): 3574-3593. [18] Wang C, Wang Z, Zhang L, et al.MiR-29c inhibits the metastasis of oral squamous cell carcinoma and promotes its cell cycle arrest by targeting SERPINH1[J]. Ann Transl Med, 2021, 9(18): 1423. [19] Du J, Zhao Y, Hu D, et al.Silencing of integrin subunit α3 inhibits the proliferation, invasion, migration and autophagy of esophageal squamous cell carcinoma cells[J]. Oncol Lett, 2022, 24(2): 271-282. [20] Fan QC, Tian H, Wang Y, et al.Integrin-α5 promoted the progression of oral squamous cell carcinoma and modulated PI3K/AKT signaling pathway[J]. Arch Oral Biol, 2019, 101: 85-91. [21] Zhao C, Shi W, Chen M.Long non-coding RNA BBOX1-antisense RNA 1 enhances cell proliferation and migration and suppresses apoptosis in oral squamous cell carcinoma via the miR-3940-3p/laminin subunit gamma 2 axis[J]. Bioengineered, 2022, 13(4): 11138-11153. [22] Saeed M, Chen F, Ye J, et al.From design to clinic: engineered nanobiomaterials for immune normalization therapy of cancer[J]. Adv Mater, 2021, 33(30): e2008094. [23] Zhang C, Zhang G, Sun N, et al.An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma[J]. Signal Transduct Target Ther, 2020, 5(1): 182-192. [24] Xu X, Zhang L, Qian Y, et al.A SERPINE1-based immune gene signature predicts prognosis and immunotherapy response in gastric cancer[J]. Pharmaceuticals (Basel), 2022, 15(11):1401. [25] Wang Y, Gu W, Wen W, et al.SERPINH1 is a potential prognostic biomarker and correlated with immune infiltration: a pan-cancer analysis[J]. Front Genet, 2021, 12: 756094. [26] Li S, Zhang N, Liu S, et al.ITGA5 is a novel oncogenic biomarker and correlates with tumor immune microenvironment in gliomas[J]. Front Oncol, 2022, 12: 844144. [27] Xiao M, Zhang J, Chen W, et al.M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1): 143-158. [28] Benzon B, Zhao SG, Haffner MC, et al.Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis[J]. Prostate Cancer Prostatic Dis, 2017, 20(1): 28-35. [29] Cheng R, Chen Y, Zhou H, et al.B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma[J]. Apmis, 2018, 126(5): 396-402. |